AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE美国呼吸与危重症医学杂志
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE(英文缩写 AM J RESP CRIT CARE),ISSN 1073-449X,eISSN 1535-4970,中文译名:美国呼吸与危重症医学杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 30.528 | Q1 |
| 2022 | 24.700 | Q1 |
| 2023 | 19.300 | Q1 |
| 2024 | 19.400 | Q1 |
| 2025 | 21.700 | Q1 |
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 最新收录文献
-
1. Stereological quantification of the different cell types in the alveolar region of the human lung.
1. 人肺肺泡区域不同类型细胞的体视学定量PMID:日期:2026-10-03该文献暂无摘要。
-
2. Lung Health after Preterm Birth: Knowledge Gaps and Respiratory Care Across the Lifespan.
2. 早产后的肺部健康：知识空白与贯穿全生命周期的呼吸护理PMID:日期:2026-10-01Prematurity affects approximately 10% of live births worldwide and contributes to substantial short and long-term morbidity, particularly respiratory disease. Approximately 35% of infants born before 32 weeks gestation are diagnosed with bronchopulmonary dysplasia (BPD). Many preterm infants regardless of BPD diagnosis also develop respiratory problems in both childhood and adulthood, more recently termed as prematurity-associated lung disease (PLD). As survival of preterm infants continues to improve, the lifetime burden of PLD and related health conditions remains high. Optimizing lung growth, minimizing the impact of comorbidities, and improving quality of life are ongoing challenges. Individuals born preterm are also at higher risk for being diagnosed with early-onset chronic obstructive pulmonary disease in adulthood. Despite these public health implications, outpatient management is often variable, and PLD remains underrecognized and heterogeneous across clinical settings. In this expert consensus statement from the BPD Collaborative, we summarize key knowledge gaps and provide pragmatic recommendations to help standardize outpatient care for PLD across the lifespan. Recommendations address models of care delivery, approaches to disease monitoring and management, and the evaluation and treatment of common comorbidities. Given limited high-quality evidence in several domains, many recommendations are necessarily based on expert opinion. Our objectives are to highlight priorities for future research, promote continuity between pediatric and adult care, and support development of evidence-based strategies to reduce underdiagnosis and undertreatment and to improve long-term outcomes for individuals born preterm.
-
3. Macrophage membrane-coated nanoparticles enhance survival in models of severe bacterial pneumonia.
3. 巨噬细胞膜包被的纳米颗粒在严重细菌性肺炎模型中提高生存率PMID:日期:2026-10-01该文献暂无摘要。
-
4. Abundance vs. Architecture: The Dual Dimensions of Pseudomonas Ecology in Bronchiectasis.
4. 丰度与结构：支气管扩张症中假单胞菌生态学的双重维度PMID:日期:2026-10-01该文献暂无摘要。
-
5. Reply to Chang: Age-Stratified Dominance Does Not Establish Age-Dependent Predictor Importance.
5. 回复Chang：年龄分层优势并不能确立年龄依赖的预测因子重要性PMID:日期:2026-10-01该文献暂无摘要。
-
7. Trends in Long-Term Oxygen Therapy Use and Modality Among Medicare Beneficiaries with COPD, ILD, and PH.
7. 患有COPD、ILD和PH的Medicare受益人中长期氧疗使用及方式的趋势PMID:日期:2026-09-30该文献暂无摘要。
-
8. Pulse versus Nonpulse Corticosteroid Therapy in Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized Clinical Trial (SAFER).
8. 脉冲与非脉冲糖皮质激素治疗特发性肺纤维化急性加重：一项多中心随机临床试验（SAFER）PMID:日期:2026-09-30Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) has high short-term mortality, yet guidelines weakly recommend corticosteroids without defining dose or duration. Pulse-dose methylprednisolone is widely used despite minimal evidence. To test the superiority of a pulse-dose corticosteroid regimen over a nonpulse regimen with respect to short-term survival in AE-IPF. In this randomised, open-label, multicenter trial at eight South Korean university hospitals, adults with AE-IPF were assigned (1:1) to receive either intravenous pulse methylprednisolone (10 mg/kg for 3 days) or nonpulse regimen (1 mg/kg for 7 days), followed by protocolised tapering and maintenance low-dose prednisolone. Primary outcomes were all-cause mortality at 28 and 90 days. Secondary outcomes included intensive care unit admission, use of mechanical ventilation or extracorporeal membrane oxygenation, death or lung transplantation at 28 and 90 days, and adverse events. The trial was registered at ClinicalTrials.gov, NCT04996303. From July 2021 to April 2024, 100 patients were randomised (pulse n = 51; nonpulse n = 49). The pulse regimen did not demonstrate lower 28-day mortality than the nonpulse regimen (10.0% vs. 14.6%; risk difference, -4.6 percentage points; 95% CI, -18.8 to 9.1; P = 0.549) or lower 90-day mortality (24.5% vs. 29.8%; risk difference, -5.3 percentage points; 95% CI, -23.1 to 12.6; P = 0.648). Treating transplantation as a competing event, Fine-Gray analysis did not demonstrate a difference in 90-day mortality. Secondary outcomes were not demonstrably different between groups. Among adults with AE-IPF, pulse-dose methylprednisolone did not demonstrate improved 28- or 90-day survival compared with a nonpulse corticosteroid regimen.
-
9. Deep learning classification of radiologic pattern is associated with progression of interstitial lung abnormalities and with survival.
PMID:日期:2026-09-29Interstitial lung abnormalities (ILA) are common, but not all progress, highlighting the need for objective computed tomography (CT)-based biomarkers for risk stratification. To determine whether deep learning-based classification of usual interstitial pneumonia (UIP) is associated with fibrosis progression and survival in individuals with ILA. Baseline and follow-up CT scans from participants without clinically diagnosed interstitial lung disease in two large observational cohorts (COPDGene and AGES-Reykjavík) were analyzed using data-driven textural analysis (DTA) to quantify fibrosis and a deep learning-based classifier (MIL-UIP) to estimate UIP likelihood. Associations of baseline MIL-UIP with DTA trajectory and survival were evaluated using linear mixed and multivariable Cox models, respectively. Baseline MIL-UIP > 0.5 was associated with relative annual DTA increases of 13.41% (95% CI: 8.10%, 18.99%; p < 0.001) and 14.10% (95% CI: 5.06%, 23.91%; p = 0.002) in COPDGene and AGES-Reykjavík, respectively. Each 0.1-point increase in MIL-UIP was associated with relative rates of DTA change that were 1.10 percentage points higher (95% CI: 0.45, 1.74; p < 0.001) in COPDGene and 1.30 percentage points higher (95% CI: 0.17, 2.45; p = 0.025) in AGES-Reykjavík. MIL-UIP > 0.5 was associated with higher mortality in COPDGene (HR 1.61; 95% CI: 1.08, 2.38; p = 0.018) and AGES-Reykjavík (HR 1.62; 95% CI: 1.01, 2.61; p = 0.046). Baseline DTA and MIL-UIP were highly associated with visual assessments of ILA, UIP, and fibrosis progression. Automated assessment of UIP-like CT features is associated with fibrosis progression and mortality in individuals with ILA, supporting its potential use for risk stratification and clinical trials enrichment.
-
10. Quantitative Computed Tomography in Progressive Pulmonary Fibrosis: Data from a Sub-Study of the Double Blind, Randomized, Placebo-controlled INBUILD Trial.
10. 进展性肺纤维化中的定量计算机断层扫描：来自双盲、随机、安慰剂对照INBUILD试验子研究的数据PMID:日期:2026-09-29Change in forced vital capacity (FVC) is an established endpoint in clinical trials in lung fibrosis, but more sensitive measures of structural deterioration are needed. Quantitative computed tomography (QCT) measurements predict FVC decline and mortality, but more information is needed on their prognostic value and response to therapy. Evaluate the prognostic potential of quantitative CT measurements derived using University of California Los Angeles (UCLA) and e-Lung (Brainomix) algorithms, and effects of nintedanib on these measurements, in patients with progressive pulmonary fibrosis (PPF). Among patients with PPF in a sub-study of the INBUILD trial (N = 474), associations between UCLA quantitative ILD and lung fibrosis (QILD and QLF) scores, e-Lung total disease extent (TDE), reticulovascular score (RVS), and weighted RVS, and ILD progression were assessed. In the placebo group, higher baseline QCT scores were associated with a greater rate of decline in FVC (mL/year) over 52 weeks. The risk of decline in FVC % predicted ≥10% or death over 52 weeks was greater with QCT scores above vs below the median; differences in restricted mean survival time ranged from 40-65 days. Nintedanib had significant effects on changes in QILD score and e-Lung TDE at week 24 (relative difference versus placebo [%]: -7 [95% CI: -11, -2; p = 0.005] and -8 [-12, -4; p < 0.001], respectively) and week 52 (-7 [-12, -2; p < 0.05] for both). Quantitative CT methods can facilitate prediction of progression and assessment of the efficacy of drugs in clinical trials in patients with PPF.